Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.58 |
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074959 | 1.00 | SLC7A5 (0.58) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL160632 | 1.00 | SLC7A5 (0.58) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL7252654 | 0.87 | CYP2C19 (0.54) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL7252652 | 0.87 | CYP2C19 (0.54) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL17449974 | 0.85 | DPP4 (0.48) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL22147488 | 0.85 | DPP4 (0.48) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL10925103 | 0.85 | DPP4 (0.48) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL5257074 | 0.85 | DPP4 (0.48) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL12240915 | 0.85 | DPP4 (0.48) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL9554473 | 0.84 | SLC7A5 (0.46) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 852 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | claimed |
| EP-4711004-A2 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | claimed |
| EP-4633657-A1 | STAPLED PEPTIDES AND METHODS THEREOF | Parabilis Medicines, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4633656-A1 | STAPLED PEPTIDES AND METHODS THEREOF | Parabilis Medicines, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2025-06-19 | — | — | US | claimed |
| CN-120152725-A | Methods of treating obesity using MC4R agonists | 节奏制药公司 | 2025-06-13 | — | — | CN | claimed |
| US-20250186539-A2 | METHODS FOR TREATING CANCER | BICYCLETX LIMITED (GB) | 2025-06-12 | — | — | US | claimed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | claimed |
| US-12263202-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | claimed |
| EP-0372537-A2 | Urea derivatives of dipeptides with enzyme-inhibiting properties, process to make them, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-06-13 | — | — | EP | claimed |
| EP-0370383-A2 | Renin-inhibiting dipeptides, process to make them, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | claimed |
| CN-1035286-A | The amino acid derivative of renin-inhibiting | HOECHST AG (DE) | 1989-09-06 | — | — | CN | claimed |
| EP-0329013-A2 | Renin-inhibiting amino acid derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-23 | — | — | EP | claimed |
| US-4855286-A | HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-08 | — | — | US | claimed |
| EP-0310015-A2 | Renin-inhibiting dipeptides, process for their preparation, medicines containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-04-05 | — | — | EP | claimed |
| EP-0255082-A2 | Renin-inhibiting di- and tripeptides, methods for their production, drugs containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-02-03 | — | — | EP | claimed |
| EP-0239874-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their application | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-10-07 | — | — | EP | claimed |
| US-4407952-A | OF GENETICALLY ENGINEERED ESCHERICHIA | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-10-04 | — | — | US | claimed |
| US-4177154-A | Synthetic aqueous based metal working fluid compositions | GAF CORPORATION (US) | 1979-12-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12263202-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | MC4R, MC5R, MC3R | SLC7A5 4056/4885PTGS1 4265/4885ALPI 4091/4885 |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | SLC7A5 2049/4885PTGS1 3113/4885ALPI 1852/4885 |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | SLC7A5 333/4885PTGS1 1376/4885ALPI 3090/4885 |
| US-20250186539-A2 | METHODS FOR TREATING CANCER | CD44, TUBB4A, TUBB3 | SLC7A5 4770/4885PTGS1 442/4885ALPI 1977/4885 |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | SLC7A5 4056/4885PTGS1 4265/4885ALPI 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.